GSK reported 2025 first-half revenue of GBP 15.5 billion (USD 20.6 billion), up 5% at constant exchange rates, driven by 16% growth in specialty medicines. HIV therapies led with GBP 3.6 billion (+10%), including long-acting injectable Cabenuva (cabotegravir + rilpivirine) at GBP 635 million (+42%). Oncology surged 47% to GBP 899 million, fuelled by PD-1 inhibitor Jemperli (dostarlimab) exceeding GBP 370 million and JAK inhibitor Omjjara (momelotinib) at GBP 250 million (+87%).

The company highlighted three US approvals this year, including antibiotic Blujepa (gepotidacin) for UTIs. Shingrix shingles vaccine sales dipped 1% to GBP 1.7 billion amid market saturation. GSK maintained its 2025 guidance of 3-5% revenue growth and 6-8% core profit increase, targeting GBP 40+ billion sales by 2031 through acquisitions like US biotech IDRx and partnerships with China-based Hengrui Pharma.

According to PharmCube's NextBiopharm® database, GSK has been increasing its deal-making activity, with total deal value in H1 2025 alone surpassing the full-year figure of any previous year. Click here to request a free trial for NextBiopharm®.